"Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Prato, Italy; Institute of Oncology of Southern Switzerland (IOSI), Bellinzona, Switzerland; Breast Unit of Southern Switzerland (CSSI), Lugano, Switzerland.
"Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Prato, Italy.
Cancer Treat Rev. 2019 Mar;74:29-34. doi: 10.1016/j.ctrv.2019.01.007. Epub 2019 Jan 25.
Patients with luminal early breast cancer are at risk of relapse, even after five years of adjuvant endocrine therapy. To date, no biomarkers have been clinically validated to identify those patients at risk of late recurrence, who might benefit from extended adjuvant endocrine therapy. In recent decades, multiple clinical trials have tested the role of extending adjuvant endocrine therapies in patients with luminal disease. However, the data currently at our disposal are conflicting. This article reviews all the major trials concerning extended adjuvant endocrine regimens, and formulates some general conclusions and hypotheses of future study.
早期腔面乳腺癌患者有复发风险，即使在接受五年辅助内分泌治疗后。迄今为止，尚无临床验证的生物标志物可识别那些有晚期复发风险、可能受益于延长辅助内分泌治疗的患者。近几十年来，多项临床试验已经测试了延长辅助内分泌治疗在腔面疾病患者中的作用。然而，我们目前掌握的数据存在矛盾。本文综述了所有关于延长辅助内分泌方案的主要试验，并得出了一些关于未来研究的一般结论和假设。
